A placebo controlled, double blind, randomised, 8-week phase IIa proof of concept study to assess the efficacy and safety of AKR 202 in patients with osteoarthritis pain.

Trial Profile

A placebo controlled, double blind, randomised, 8-week phase IIa proof of concept study to assess the efficacy and safety of AKR 202 in patients with osteoarthritis pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Adefovir dipivoxil (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Akron Molecules
  • Most Recent Events

    • 22 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Dec 2013 New source identified and integrated (ClinicalTrials.gov; NCT02003118).
    • 06 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top